Hansteen V, Endresen K, Hellemann H, Eriksen I I, Brorssen O, Ekeli T, Day M, Baber N S
Br J Clin Pharmacol. 1984 May;17(5):579-84. doi: 10.1111/j.1365-2125.1984.tb02393.x.
Ten male patients with chronic stable angina pectoris completed a randomized, double-blind cross-over study, with matched placebo run-in period (P), to compare the effects of a long-acting preparation of propranolol (LA, 160 mg once a day) with that of conventional propranolol (CP, 40 mg four times a day) each given for 14 days. Response was assessed by symptom-limited bicycle ergometry, degree of ST segment depression, daily anginal attack rate and glyceryl trinitrin consumption (GTN). Heart rate and ventricular extra-systolic frequency (VES) were recorded by 24 h Holter monitor. Bicycle ergometry was performed and a trough blood sample taken for propranolol estimation on day 14 prior to the morning dose. Both formulations increased total work capacity (P 3412, LA 4095, CP 3697 kpm/min), reduced rate-pressure product (P 21896, LA 16011, CP 15609 mm Hg beats/min), and degree of ST segment depression (P 4.53, LA 2.48, CP 2.43), but without differences between the formulations. Daily anginal attack rate was reduced from 30 (placebo) to 7.5 (CP) and 14.5 (LA) (P less than 0.05 between treatment groups). There was a reduction in daily GTN consumption by both treatments. The heart rate and total number of VESs during 24 h was similar in the two treatment groups and was reduced in comparison with placebo. Both formulations were well tolerated. Long-acting propranolol is an effective and well-tolerated alternative to conventional propranolol in the treatment of chronic stable and stress-induced angina, and in reducing VES frequency.
十名慢性稳定型心绞痛男性患者完成了一项随机、双盲交叉研究,设有匹配的安慰剂导入期(P),以比较长效普萘洛尔制剂(LA,每日一次,160毫克)与常规普萘洛尔(CP,每日四次,40毫克)各给药14天的效果。通过症状限制的自行车测力计、ST段压低程度、每日心绞痛发作率和硝酸甘油消耗量(GTN)评估反应。通过24小时动态心电图监测仪记录心率和室性早搏频率(VES)。在第14天早晨给药前进行自行车测力计测试并采集血样以测定普萘洛尔。两种制剂均增加了总工作能力(P组3412、LA组4095、CP组3697千帕米/分钟),降低了心率血压乘积(P组21896、LA组16011、CP组15609毫米汞柱·次/分钟)以及ST段压低程度(P组4.53、LA组2.48、CP组2.43),但两种制剂之间无差异。每日心绞痛发作率从30次(安慰剂)降至7.5次(CP)和14.5次(LA)(治疗组之间P<0.05)。两种治疗均使每日GTN消耗量减少。两个治疗组24小时内的心率和VES总数相似,与安慰剂相比均有所降低。两种制剂耐受性良好。长效普萘洛尔在治疗慢性稳定型和应激性心绞痛以及降低VES频率方面是一种有效且耐受性良好的常规普萘洛尔替代药物。